Recently, was demonstrated that the mTOR pathway is overexpressed in NEC (11). Based on the activity of Everolimus in the treatment of patients with well and moderately differentiated p-NET and on the evidence that even poorly differentiated forms express the pathway of m-TOR is conceivable that Everolimus could be active even in NEC. In particular we want to test the hypothesis that a maintenance therapy (or an early second line) with Everolimus 10 mg/daily in non progressive patients after first line chemotherapy could improve outcome prolonging progression free survival (PFS).